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Abstract
Background: Ion channel transient receptor potential membrane melastatin 6 and 7 (TRPM6 and
TRPM7) play a central role in magnesium homeostasis, which is critical for maintaining glucose and
insulin metabolism. However, it is unclear whether common genetic variation in TRPM6 and TRPM7
contributes to risk of type 2 diabetes.
Methods: We conducted a nested case-control study in the Women's Health Study. During a
median of 10 years of follow-up, 359 incident diabetes cases were diagnosed and matched by age
and ethnicity with 359 controls. We analyzed 20 haplotype-tagging single nucleotide
polymorphisms (SNPs) in TRPM6 and 5 common SNPs in TRPM7 for their association with diabetes
risk.
Results: Overall, there was no robust and significant association between any single SNP and
diabetes risk. Neither was there any evidence of association between common TRPM6 and TRPM7
haplotypes and diabetes risk. Our haplotype analyses suggested a significant risk of type 2 diabetes
among carriers of both the rare alleles from two non-synomous SNPs in TRPM6 (Val1393Ile in exon
26 [rs3750425] and Lys1584Glu in exon 27 [rs2274924]) when their magnesium intake was lower
than 250 mg per day. Compared with non-carriers, women who were carriers of the haplotype
1393Ile-1584Glu had an increased risk of type 2 diabetes (OR, 4.92, 95% CI, 1.05–23.0) only when
they had low magnesium intake (<250 mg/day).
Conclusion: Our results provide suggestive evidence that two common non-synonymous TRPM6
coding region variants, Ile1393Val and Lys1584Glu polymorphisms, might confer susceptibility to
type 2 diabetes in women with low magnesium intake. Further replication in large-scale studies is
warranted.
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Background
Magnesium is an essential mineral derived primarily from
dietary sources, including whole-grains, green leafy vege-
tables, legumes, and nuts [1]. Adequate magnesium
intake is critical in maintaining magnesium balance and
normal magnesium-dependent cellular reactions in the
human body. Magnesium deficiency has been correlated
with a cluster of metabolic abnormalities and associated
chronic diseases such as oxidative stress, systemic inflam-
mation, endothelial dysfunction, insulin resistance,
hypertension, type 2 diabetes, and coronary heart disease
[2-6]. Although the precise mechanisms underlying mag-
nesium metabolism are unclear, magnesium homeostasis
in the human body seems to be tightly regulated via the
balance between intestinal absorption and renal excre-
tion. Recent studies suggest that transient receptor poten-
tial membrane melastatin 6 and 7 (TRPM6 and TRPM7),
two members of the "transient receptor potential" (TRP)
family of cation channels, may play a central role in the
regulation of magnesium homeostasis [7-10].
The TRPM6 gene, located on chromosome 9q21.13, com-
prises 39 exons spanning 163 kb of genomic sequence
and encodes 2022 amino acids [11]. TRPM6 is thought to
be an ion channel subunit primarily expressed in intesti-
nal epithelia and kidney tubules that may play an impor-
tant role in intestinal and renal magnesium handling
[12,13]. Several loss-of-function mutations in TRPM6
have been identified among patients with autosomal-
recessive familial hypomagnesemia with secondary
hypocalcemia [12-14]. TRPM7, located on chromosome
15q21, spans 127 kb of DNA sequence and encodes a pro-
tein of 1865 amino acids. TRPM7 is ubiquitously
expressed in various tissues or cell lines [8,9] and may be
part of a magnesium sensing and/or uptake mechanism
underlying cellular magnesium homeostasis [8,9].
Although TRPM6 and TRPM7 share 52% homology [15],
their biological functions are not redundant, and they can
form functional heterometic channels with different per-
meability [16]. Thus, these two genes are candidate genes
for evaluating the genetic basis of hypomagnesemia-
related metabolic traits such as the common form of type
2 diabetes. To date, no study has assessed common
genetic variation in these two genes or their contribution
to susceptibility to chronic metabolic disorders highly
correlated with hypomagenesemia. Furthermore, a mag-
nesium-deficient diet was shown to upregulate TRPM6
mRNA expression in mice [17]. Low serum magnesium
levels caused by TRPM6 mutations among HSH patients
can be ameliorated by oral supplementation of high doses
of magnesium [18]. Thus, it is important to further exam-
ine in human population data whether magnesium intake
modifies any common genetic effects of TRPM6  and
TRPM7 on diabetes risk.
We therefore conducted a prospective nested case-control
study among postmenopausal women in the Women's
Health Study to investigate the association between com-
mon variations of the TRPM6 and TRPM7 genes and the
risk of type 2 diabetes. We specifically tested the following
hypotheses: (1) common genetic variants in TRPM6 and
TRPM7 are associated with risk of developing type 2 dia-
betes because of their critical functions on maintaining
magnesium homeostasis; and (2) The genetic association,
if any, is more pronounced among women with inade-
quate magnesium intake.
Methods
Study population
The Women's Health Study, begun in 1993, is a rand-
omized, double-blind, placebo-controlled, 2 × 2 factorial
trial of low-dose aspirin and vitamin E for the primary
prevention of CVD and cancer among 39,876 US female
health professionals aged 45 years and older free of cancer
(other than nonmelanoma skin cancer), and cardiovascu-
lar disease [19,20] at baseline. Of the 39,876 participants,
28,345 (71%) provided baseline blood samples. Of these
28,345, we restricted our study to 12,304 women free of
diabetes at baseline who were not currently receiving hor-
mone replacement therapy and were postmenopausal at
the time of blood collection. By February 2005 with 10
years of follow up, 366 of these initially healthy women
had developed incident diabetes. Using the principle of
risk-set sampling to randomly select controls from the
cohort person-time [21], controls providing baseline
blood samples were matched in 1:1 ratio to cases by age
(within 1 year), duration of follow up (within 1 month),
race, and fasting status at time of blood draw (72% pro-
vided fasting blood, defined as ≥ 10 hrs since last meal).
Based on these criteria, a total of 359 cases and 359 con-
trols were selected. This study was conducted according to
the ethical guidelines of Brigham and Women's Hospital.
Data collection
On the baseline questionnaire, we collected detailed
information on demographics, medical history, and life-
style factors. In the enrollment questionnaire, participants
provided information on lifestyle exposures including cig-
arette smoking status (never, past, current), aerobic phys-
ical activity (never, <1/week, 1/week, 2–3 times/week, 4–
6 times/week, daily), total intakes of beer, wine, and liq-
uor (g/day), use of aspirin before the trial (yes, no), use of
multivitamin (yes, no), and use of postmenopausal hor-
mone therapy (never, past, current), Moreover, partici-
pants reported their medical history characteristics such as
age, height, weight, history of type 2 diabetes, and family
history of diabetes in first-degree relatives.
As described previously, a semiquantitative food-fre-
quency questionnaire (SFFQ) at baseline was used toBMC Medical Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2350/10/4
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assess dietary nutrient intake [22]. Each nutrient was
adjusted for total energy using the residual method [23].
In populations of nurses and health professionals, this
SFFQ has demonstrated reasonably good validity as a
measure of long-term average dietary intakes [24]. The
Pearson correlation coefficient between magnesium
intake assessed by SFFQ and 2 weeks of diet records was
0.76 [25]. The use of multivitamin supplements was taken
into account to assess intake of supplemental magnesium.
Total magnesium represents the sum of magnesium
intake from both dietary and supplemental sources.
Ascertainment of diabetes
After excluding prevalent cases at baseline, all eligible par-
ticipants were asked annually whether and when they had
been diagnosed with diabetes since completing the previ-
ous questionnaire. Women self-reporting incident diabe-
tes in annual follow-up were mailed supplementary
questionnaires to confirm diabetes symptoms, diagnostic
tests, and treatments. Diabetes was confirmed according
to the American Diabetes Association (ADA) criteria of
1997 [26]. Previous WHS diabetes validation via physi-
cian-led telephone interviews and self-administered sup-
plementary questionnaires both yielded positive
predictive values >91%, and confirmation of diabetes via
combined supplementary questionnaire and medical
records was 99% [27,28].
SNP selection and genotyping
We initially surveyed common SNPs with minor allele fre-
quency (MAF) ≥ 5% from the public accessible database,
the National Center for Biotechnology Information data-
base SNP (NCBI dbSNP) supplemented by the CEU Hap-
Map database of the International HapMap project. Our
goal was to select a minimal set of common SNPs (MAF ≥
5%) to capture the common genetic variability across the
genomic regions of the TRPM6  (223 kb) and of the
TRPM7 (187 kb) genes, including their corresponding 30
kb 5' upstream and 30 kb 3' downstream regions. SNPs
were selected based on the following criteria: 1) Function-
ality priority: non-synonymous coding SNPs, splicing-site
SNPs, and promoter SNPs were kept; and 2) minor allele
frequency (MAF) ≥ 5% in at least one Caucasian popula-
tion [29]. In total, a set of 25 SNPs (20 for TRPM6 and 5
for TRPM7) were chosen and genotyped in the entire case-
control sample (Table 1).
DNA was extracted from the buffy coat fraction of centri-
fuged blood using a QIAmp blood kit (Qiagen, Chats-
worth, CA) at the Dana Farber/Harvard Cancer Center
High Throughput Genotyping Core (David J. Hunter, MD,
Director). DNA samples were genotyped using Taqman
single nucleotide polymorphism allelic discrimination by
means of an ABI 7900 HT (Applied Biosystems, Foster
City, CA). The primers and probes were custom-designed
by the ABI Taqman system (PE Biosystems, Foster City,
CA). Following PCR amplification, end-point fluores-
cence was read with the Applied Biosystems Primer 7900
HT instrument and genotypes were assigned using
SDS2.2.2 Allelic Discrimination Software (Applied Bio-
systems, Foster City, CA) by a technician blinded to sam-
ple identification numbers. Replicate quality control
samples (10%) were included and genotyped with >99%
concordance.
Statistical analyses
Distributions or proportions of baseline characteristics of
study subjects were examined according to case-control
status. Student's t-test and chi-square test were used for
comparisons of means and proportions. We assessed each
SNP for the Hardy-Weinberg equilibrium (HWE) test
using the chi-square test.
Pairwise LD between SNPs was assessed using Lewontin's
D' statistic and the squared correlation statistic r2. The
Haploview program was used to calculate the LD coeffi-
cient and define haplotype blocks [30,31]. For each SNP,
we tested for allelic association with diabetes risk under
dominant, recessive, and additive models. We used
unconditional logistic regression to estimate odds ratios
(ORs) and 95% confidence intervals (CIs) for each SNP
with diabetes risk for each genetic model, respectively. We
made adjustments for multiple confounding variables
including matching factors (age and ethnicity), BMI (con-
tinuous), smoking (current, former, and never), alcohol
use (rarely/never drinkers, 1–3 drinks/month, 1–6 drinks/
week, and 1 or more drinks/day), exercise (rarely/never, 1,
2–3, 4–6 and ≥ 7 times/week), and family history of dia-
betes (yes, no).
Haplotypes inferred from all SNPs and all haplotypes
within each LD block were tested for association with type
2 diabetes. We estimated haplotype frequency from
phase-unknown genotype data using the expectation-
maximization (EM) algorithm [32]. For each individual
and each haplotype, h, the haplotype dosage estimate (i.e.
an estimate of the number of copies of haplotype h) was
computed using the individual's genotype data and hap-
lotype frequency estimates obtained from the combined
(cases+controls) data set [32,33]. Only haplotypes with
estimated frequencies ≥ 1% in the combined cases and
controls were included for analyses. We first performed
global likelihood ratio tests to examine whether the fre-
quency distributions of the common haplotypes differed
between cases and controls by comparing a model with
additive effects on the log odds scale for each common
haplotype (using the most common halpotype as the ref-
erence) to the intercept-only model. As compared to the
corresponding non-carriers of each haplotype, we also cal-
culated haplotype-specific ORs and 95% CIs for carriers of
each specific haplotype from logistic regression analyses.BMC Medical Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2350/10/4
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A sliding window (window width = 2) haplotype-based
analysis was performed to identify a "sub-haplotype" that
would be most significantly associated with the disease
outcome. The omnibus likelihood ratio test was used to
test the association significance in the total samples, and
in subsamples stratified by levels of magnesium intake. A
-log10p > 2.88 (p < 0.0013) was used as the global signifi-
cance threshold by Bonferroni correction for 19 window
frames.
Stratified analyses were conducted to examine whether
the association between the TRPM6  and TRPM7  geno-
types and risk of type 2 diabetes was modified by magne-
sium intake. The cutpoints for magnesium levels were
prespecified by those for quintiles among controls. Inter-
actions between the genotype/haplotype and magnesium
intake were assessed by comparison of regression models
with and without the product terms between the genotype
and stratifying variables using a likelihood ratio test.
All reported P-values were 2-tailed, and statistical signifi-
cance was defined at the α = 0.05 level. Statistical analyses
were performed using SAS statistical package (version 9.0
for window; SAS Institute, Cary, NC). In addition, we per-
Table 1: The location, minor allele frequency, and crude association analyses of 25 SNPs spanning both TRPM6 and TRPM7 loci
Minor allele frequency (MAF) P values for crude associationb
SNP Alleles
(major/minor)
Locationa Cases Controls Genotypic 
recessive
Genotypic 
additive
Genotypic 
dominant
rs4745363 (46) T>A Intron 1 0.46 0.42 0.08 0.18 0.59
rs10869447 (45) A>G Intron 3 0.39 0.35 0.05 0.25 0.79
rs11144108 (44) T>G Intron 6 0.36 0.35 0.20 0.67 0.77
rs7867868 (43) C>T Intron 6 0.33 0.32 0.56 0.75 0.41
rs7045949 c(42) C>T 
(in only European 
whites)
Intron 7 0.41 0.42 0.91 0.76 0.59
rs1012710 (41) T>C Intron 12 0.30 0.30 0.93 0.97 0.91
rs10512038 (40) T>C Intron 14 0.25 0.28 0.83 0.28 0.21
rs7859201d(39) A>C
(Leu708Leu)
Exon 17 0.39 0.43 0.32 0.11 0.13
rs3858116 (38) G>A Intron 18 0.38 0.40 0.78 0.46 0.39
rs2151424 (37) C>T Intron 19 0.26 0.28 0.13 0.37 0.74
rs2151423 (36) A>G
(whites only)
Intron 19 0.45 0.46 0.43 0.91 0.60
rs6560408 (35) C>T Intron 23 0.39 0.40 0.90 0.74 0.56
rs3750425e(34) G>A (Val1393Ile) Exon 26 0.097 0.095 0.29 0.86 0.89
rs2274924f(33) A>G
(Lys1584Glu)
Exon 27 0.18 0.18 0.42 0.79 0.51
rs2769195 (32) T>C Intron 27 0.44 0.42 0.03 0.33 0.69
rs1327824 (31) G>C Intron 31 0.09 0.11 0.50 0.46 0.53
rs875034 (30) A>G Intron 33 0.42 0.42 0.91 0.84 0.83
rs944857 (29)g T>C Intron 36 0.02 0.009 -- 0.07 0.07
rs539079 (28) A>G Intron 36 0.10 0.09 0.67 0.91 0.99
rs514348 (27) T>A Intron 38 0.41 0.40 0.09 0.80 0.35
TRPM7
rs8042919h(51) G>A 
(Thr1482Ile)
Exon 28 0.10 0.12 0.27 0.19 0.27
rs3109881(50) G>A 3'UTR 0.36 0.41 0.15 0.04 0.07
rs10519279 (49) G>C 3'UTR 0.16 0.19 0.40 0.19 0.22
rs3131597 (48) C>T 3'UTR 0.41 0.46 0.10 0.13 0.36
rs3098198 (47) A>G 3'UTR 0.47 0.41 0.13 0.03 0.03
a: The location was based on the contiguous position (reference NT_023935.17 for TRPM6 and NT_010194.16 for TRPM7);
b: Adjusted for two matching variables (age and race).
c: Exon-intron boundary region;
d: Synonymous polymorphism (Leu708Leu)
e: Non-synonymous polymorphism in TRPM6: Protein residue: Val1393 Ile
f: Non-synonymous polymorphism in TRPM6: Protein residue: Lys1584Glu
g: No homozygosity observed for rare allele A;
h: Non-synonymous polymorphism in TRPM7: Protein residue: Ile482ThrBMC Medical Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2350/10/4
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formed bioinformatics analyses to address the potential
functional relevance of three common coding SNPs in
TRPM6 and TRPM7. Several algorithms including PMut
[34], PolyPhen [35], and SIFT [36] were employed to pre-
dict the impact of these amino acid substitutions on pro-
tein structure and activity. The principles for these
algorithms are sequence conservation over evolutionary
time, the physical and chemical properties of the
exchanged residues, and/or protein structural domain
information. Different algorithms emphasize different
aspects of assumptions, quantitative measures, and
dynamic databases, but these algorithms are highly capa-
ble of predicting the impact of amino acid substitutions
on function, consistent with results from biochemical
analyses (>80% concordance rate). Polymorphisms
within highly conserved regions are likely to be of greater
functional significance than those within more diverged
regions. Our cross-species comparison approach for
TRPM6 and TRPM7 was based solely on the availability of
relevant information from the NCBI Genbank database.
To provide some indirect evidence for protein sequence
changes among different species, cross-species compari-
son of the protein sequences was performed for two
TRPM6  segments encompassing the two non-synony-
mous SNPs, V1393I and K1584E in human, chimpanzee,
and mouse and a TRPM7 segment encompassing the non-
synonymous SNP, T1482I in human, Sheep, mouse, and
zebra fish. Protein sequence alignments were performed
by use of ClustalX, version 1.81 [37].
Results
Basic characteristics of the population by case-control sta-
tus are shown in Table 2. Overall, diabetes cases had a
higher prevalence of traditional diabetes risk factors at
baseline than controls. The location, minor allele, and
allele frequency for all 25 SNPs are shown in Table 1.
Their observed genotype frequencies, except for
rs7867868 (P = 0.03), were within HWE among the con-
trols. We examined whether each of the SNPs chosen was
significantly associated with type 2 diabetes under three
genetic models (additive, recessive, and dominant mod-
els). As showed in Table 1, only one SNP in TRPM6 was
significantly associated with diabetes risk in the recessive
model (rs2769195, P = 0.03). Of the 5 TRPM7  SNPs,
rs3109881 and rs3098198 showed significant associa-
tions with diabetes risk (rs3109881, additive P = 0.04; and
rs3098198, additive P = 0.03 and dominant P = 0.03).
These results were likely to be false positives, because they
did not remain statistically significant after further adjust-
ment for more covariates or multiple comparisons.
The LD structure and haplotype blocks were shown for 20
SNPs in TRPM6 (Figure 1) and 5 SNPs in TRPM7 (Figure
2) among controls. The 20 SNPs in TRPM6 fall into six
blocks with high LD and different sizes. Notably, the two
non-synonymous SNPs (rs3750425 and rs2274924) in
TRPM6 were 762 bp apart and yet not in complete LD (D'
= 0.98; r2 = 0.46). For TRPM7, rs8042919 (Ile1482Thr in
exon 29) was in tight LD with all other SNPs in TRPM7
(D' = 1.00; r2 = 0.10–0.59).
Haplotype analyses of the 20 SNPs spanning the TRPM6
region did not reveal any significant associations. There
was no evidence for haplotypic associations with all
derived haplotypes based on all 20 TRPM6 SNPs and 5
TRPM7 SNPs. Haplotype analysis in each of these blocks
did not provide evidence of statistically significant associ-
ations with diabetes risk (data not shown). Overall, a glo-
bal test for differences in risk according to common
haplotypes (≥ 1%) inferred from 20 SNPs over TRPM6
was not statistically significant (P = 0.31). There was no
significant association with haplotypes in any single
block: p values for global testing of haplotype associations
were 0.69 for block 1, 0.96 for block 2, 0.12 for block 3,
0.92 for block 4, 0.85 for block 5, and 0.33 for block 6.
Neither was there any evidence of association between
common TRPM7 haplotypes and diabetes risk (P for glo-
bal test = 0.43).
We conducted a sliding window (window width = 2) hap-
lotype-based analyses to examine the genetic associations
of TRPM6 with risk of type 2 diabetes. There were a total
of 19 window frames for the 20 SNPs. Overall, there were
Table 2: Baseline characteristics of patients with type 2 diabetes 
and control participants.
Characteristicsa Cases
n = 359
Controls
n = 359
P valueb
Age, years 60.3 ± 6.1 60.3 ± 6.1 --c
Race (Caucasian), % 92.5 92.5 --c
BMI, kg/m2 30.9 ± 6.1 26.0 ± 5.0 <0.0001
Cigarette smoking (%)
Never 47.5 49.6 0.85
Past 38.0 36.8
Current 14.5 13.7
Physical activity, %
Rarely/never 51.1 39.6 0.008
1 to 3 times per month 18.2 21.7
> 1 time per week 30.7 38.7
Alcohol consumption, %
Rarely/never 60.7 47.1 0.0006
1 to 3 times per month 13.7 15.3
>1 time per week 25.6 37.6
Family history of diabetes (%) 48.5 24.0 <0.0001
Dietary factors
Total calorie intake, kcal/d 1809 ± 592 1722 ± 554 0.05
Magnesium intake, mg/d d 329 ± 70.5 348 ± 83.0 0.001
a All data are mean ± SD unless indicated otherwise;
b P value from chi-square and t tests;
c Matching variables;
d Magnesium intake was the total amount of magnesium from both 
food sources and multivitamin supplements and was energy-adjusted.BMC Medical Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2350/10/4
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no significant associations for any 2-SNP "sub-haplotype"
in any case-control samples (data not shown). When we
stratified all cases and controls by magnesium intake, only
one 2-tSNP "sub-haplotype", rs3750425-rs2274924 ( 2 =
24.14, d.f. = 7, p = 0.0011), reached global significance
(i.e. -log10 p > 2.88) for women with magnesium intake in
the lowest 20% (<250 mg/day) (Figure 3). These two
SNPs were both non-synonymous and in a tight LD block,
with the frequency of carriers for both rare alleles of these
two SNPs (the A allele of rs3750425 and the G allele of
rs2274924) representing 9.3% in all the control samples.
As shown in Table 3, there were no significant associa-
tions between any individual non-synonymous SNP and
diabetes (under dominant models), among women with
either low or high magnesium intake. Only among
women with low magnesium intake was the haplotype
based on 2SNPs in TRPM6 significantly associated with
diabetes risk, although statistical power in our subgroup
analyses became weak. Among women with low magne-
sium intake, ORs and 95% CIs in a comparison with car-
riers of both common alleles (G-A) were 4.92 (1.05–23)
for the haplotype A-G and 0.56 (0.09–3.52) for the hap-
lotype G-G. Adjustment for more potential confounders
did no materially change the results.
In addition, our bioinformatics analyses provided some
indirect evidence for prediction of the effects of an amino
acid substitution SNP on protein structure and function
Location and linkage disequilibrium (LD) map of 20 SNPs in TRPM6 Figure 1
Location and linkage disequilibrium (LD) map of 20 SNPs in TRPM6. The relative physical position of each SNP is 
given in the upper diagram. Exons are represented by solid bars; intronic and 5' and 3' regions are represented by solid lines. 
The dbSNP reference numbers are indicated below each SNP. The pairwise linkage disequilibrium (LD) coefficient D' for the 
control participants were calculated using Haploview. Each diamond for each SNP combination indicates the pairwise LD 
between all tSNPs, with red indicating strong LD (D' > 0.8) and a logarithm of odds score of >2.0. LD strength between the 
chosen SNPs is determined by the 90% confidence limits of D' statistic. Haplotype blocks were identified using Haploview.
5’
1                                         4                      8                  12              16                 20        24                                  28       32    36           39 
3’
163 kb
TRPM6 gene
D’ = 1 &  LOD ≥ ≥ ≥ ≥ 2
D’< 1 &  LOD ≥ ≥ ≥ ≥ 2
D’ < 1 &  LOD < 2
D’ = 1 &  LOD < 2BMC Medical Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2350/10/4
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(Figure 4 and Table 4). One non-synonymous SNP
(rs2274924; K1584E) in TRPM6 seemed to be evolution-
arily conservative and were predicted to be neutral using
PMut prediction algorithm; however, measures of
Polyphen and SIFT scores predicted that rs3750425
(V1393I) in TRPM6 and rs8042919 (T1482I) in TRPM7
might have a negative impact on protein activity. It should
be noted that these algorithms are unable to predict the
impact of multiple amino acid substitutions in a subunit
on the activity of the protein. Thus, we cannot completely
rule out the possibility that haplotypes based on multiple
coding SNPs are functionally important.
Discussion
Overall, we observed no significant associations between
the TRPM6 and TRPM7 genetic variants, individually or
jointly, with risk of type 2 diabetes in women. However,
women who were homozygous carriers of both the rare
alleles of two non-synonymous SNPs in TRPM6 and had
low magnesium intake had a significantly higher risk of
type 2 diabetes, although these findings may have been
due to chance and further large-scale studies are needed to
confirm these subgroup analyses.
To the best of our knowledge, this is the first population
study to comprehensively investigate TRPM6 and TRPM7
as potential candidate genes for the common form of type
2 diabetes. On the basis of the publicly accessible dataset,
we focused on common SNPs including intronic SNPs,
synonymous SNPs, and non-synonymous SNPs to charac-
terize genetic variation spanning the TRPM6 gene, includ-
ing at least 30 kb upstream and downstream of the coding
Location and linkage disequilibrium (LD) map of 5 SNPs in TRPM7 using Haploview Figure 2
Location and linkage disequilibrium (LD) map of 5 SNPs in TRPM7 using Haploview. The relative physical position 
of each SNP is given in the upper diagram. Exons are represented by solid bars; intronic and 5' and 3' regions are represented 
by solid lines. Each diamond for each SNP combination indicates the pairwise LD between all tSNPs, with red indicating strong 
LD (D' > 0.8) and a logarithm of odds score of >2.0. LD strength between the chosen SNPs is determined by the 90% confi-
dence limits of D' statistic.BMC Medical Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2350/10/4
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regions. There may be some unknown causal SNPs includ-
ing splicing SNPs and SNPs in the promoter region of
TRPM6 that likely regulate gene expression. However, we
could not identify regulatory SNPs without functional
data and did not find any common SNP in the promoter
region. Although we did not sequence genomic regions in
TRPM6 in our study samples, empirical data have demon-
strated that tSNPs selected from the HapMap population
samples can effectively capture common variation and
provide good power to detect a modest association in
many other independent samples [38]. We cannot com-
pletely rule out the possibility of rare but functional vari-
ants (with an allele frequency <5%). Nevertheless, such
rare alleles may not be major contributors to the most
common late-onset form of type 2 diabetes with a high
prevalence and incidence in the general population.
Our most significant statistical finding focused on two
coding SNPs in TRPM6 among women with insufficient
magnesium intake (at the lowest 20 percentile) (i.e. <250
mg/d), close to three quarters of the RDA for adult
women. Among women, only those with low magnesium
intake were found to have increased risk of type 2 diabe-
tes. In our study population, approximately 33% are het-
erozygous for the rare G allele of rs2274924 and 18%
heterozygous for the allele A of rs3750425. Both SNPs are
also very common in populations with various genetic
backgrounds; the HapMap population frequencies are
0.07–0.21 for the rs3750425 A allele (1393 Ile) and 0.15–
0.36 for the rs2274924 G allele (1584Glu) in four ethnic
groups. Two changed amino acids are located between the
coiled region and kinase near the C-terminal [14].
Although such two amino acid substitutions in this region
are unlikely responsible for direct regulation of the
TRPM6 channel trans-membrane structures and kinase
activity, they may alter protein conformation and thus
reduce TRPM6 channel activity. Our bioinformatics
approaches indicated that these coding SNPs in highly
conserved region might be functionally significant,
although further functional analysis should be warranted.
There is also the possibility that these SNPs are in high LD
with untyped SNPs that directly affect channel activity.
Alternatively, two amino acid substitutions may be neces-
sary to influence channel protein structure and function.
Individuals with both rare alleles, whose TRPM6 channel
function is deficient in magnesium absorption, may be
Table 3: Association between three non-synonymous polymorphisms in TRPM6 and TRPM7 and the risk of type 2 diabetes among 
women stratified by magnesium intake
Magnesium Intake
Number Low
(<250 mg/day)
High
(≥ 250 mg/day)
Genotypea Cases Controls Age, race, and BMI-
adjusted OR (95% CI)
Multivariate-adjusted 
OR (95% CI)b
Age, race, and BMI-
adjusted OR
(95% CI)
Multivariate-adjusted 
OR (95% CI)b
TRPM6
rs3750425 (Val1393Ile)
GG 279 287 1.00 1.00 1.00 1.00
GA/AA 60 64 4.32
(0.98–19.1)
5.29
(0.96–29.1)
0.90
(0.57–1.44)
0.80
(0.49–1.31)
rs2274924 
(Lys1584Glu)
AA 239 230 1.00 1.00 1.00 1.00
AG/GG 106 114 2.19
(0.68–7.11)
2.16
(0.58–8.07)
0.89
(0.61–1.31)
0.88
(0.59–1.31)
Haplotypec
0–0 (G-A) 82.4% 81.5% 1.00 1.00 1.00 1.00
1–1 (A-G) 9.86% 9.30% 4.92
(1.05–23.0)
5.80
(1.01–33.5)
0.95
(0.62–1.44)
0.87
(0.56–1.35)
0–1 (G-G) 7.72% 9.03% 0.56
(0.09–3.52)
0.44
(0.06–3.26)
0.94
(0.61–1.46)
1.03
(0.66–1.63)
TRPM7
rs8042919 (Thr1482Ile)
GG 278 272 1.00 1.00 1.00 1.00
AG/AA 63 76 2.48
(0.48–12.7)
3.60
(0.56–23.0)
0.93
(0.60–1.44)
0.97
(0.61–1.52)
a: Only haplotypes with frequency > 1% are reported
b: Adjusted for matching variables (age and race), BMI, smoking, alcohol use, exercise, and family history of diabetes.
c: Haplotypes (rs3750425/rs2274924) were inferred from phase-unknown genotype data using the expectation-maximization algorithm.BMC Medical Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2350/10/4
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more prone to magnesium deficiency through low intake
and in turn to an increased risk of diabetes. If our finding
is replicated in future studies, it will suggest that common
genetic variation in the TRPM6 locus known to harbor
severe mutations causing monogenic magnesium defi-
ciency confers a modest susceptibility to the risk of type 2
diabetes in a small subgroup of the general population.
We found no significant evidence for an association
between TRPM7 genetic variants and diabetes. Given the
limited number of genotyped SNPs (n = 5) across TRPM7
(128 kb) from the reference panel (HapMap database), it
is likely that they are not sufficient to capture the vast
majority of the genetic variability of TRPM7. Biologically,
TRPM7 is ubiquitously expressed and its constitutive acti-
Sliding window analysis for haplotype-disease associations Figure 3
Sliding window analysis for haplotype-disease associations. Haplotype was reconstructed by 2-SNP sets. The omnibus 
test was used for the TRPM6 haplotype-type 2 diabetes associations for each sliding window set. Empirical p-value was based 
on permutation test. The dashed line represents a -log10P value of 2.88 (corresponding to P = 0.0013), which was used as the 
global significance threshold by Bonferroni correction for 19 window frames.
Table 4: Computational predictions of the functional significances of 3 non-synonymous SNPs in the TRPM6 and TRPM7 genes
rs# SNP Functional Prediction Algorithm
PMut Score
[Reliability index]a
PolyPhen scoreb SIFT Scorec
rs3750425 Val1393Ile
(TRPM6)
0.0250 [9]
(Neutral)
1.026
(Borderline)
0.04
(Intolerant)
rs2274924 Lys1584Glu
(TRPM6)
0.2565 [4]
(Neutral)
0.256
(Benign)
<0.001
(Intolerant)
rs8042919 Thr1482Ile
(TRPM7)
0.7987 [5]
(Pathological)
1.079
(Borderline)
0.03
(Intolerant)
a. The range of the PMut prediction score is from 0 to 1; a score over 0.5 suggests an effect on protein function and a score <0.5 indicates that the 
substitution is likely neutral. The range of the reliability index is from 0 to 9; the higher the number, the more reliable is the prediction.
b. PolyPhen Scores: 1.49–1.25 are designated as "Potentially damaging to function"; 1.24–1.00, "Borderline"; and <1.00, "Benign".
c. The SIFT scores are limited to the range of 0.0 to 1.0. Variants are classified as "Intolerant" (0.00–0.05), "Potentially intolerant" (0.051–0.10), 
"Borderline" (0.101–0.20), and "Tolerant" (0.201–1.00).BMC Medical Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2350/10/4
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vation is required for cellular survival. Animal studies
showed that dietary magnesium restriction did not alter
TRPM7  mRNA expression in mouse kidney and colon
[17]. We therefore hypothesize that TRPM7, as a house-
keeping gene regulating cellular magnesium metabolism,
may truly have limited genetic variability.
The precise mechanisms for the regulatory role of TRPM6
and TRPM7  in magnesium homeostasis remain largely
undefined. TRPM6 is a magnesium-permeable channel
protein localized to the apical domain of the distal convo-
luted tubule and the brush-border membrane of the
absorptive cells in intestine and plays an important role in
active magnesium handling in the small intestine and kid-
ney. Rare mutations in TRPM6, either incomplete or com-
plete loss-of-function, have been associated with cases of
autosomal-recessive hypomagnesemia with secondary
hypocalcemia [12,13]. Clinical data show that sufficient
magnesium intake can partially compensate for the severe
magnesium deficiency caused by genetic defect in the
TRPM6 gene [13]. It has been hypothesized that intestinal
magnesium absorption occurs via two different pathways:
an active transcellular transport and a passive paracellular
passive transport [13]. High magnesium concentrations
in intestinal tracts may overcome the genetic defects of
magnesium absorption and independently increase mag-
nesium absorption via the passive paracellular pathway.
In contrast, when dietary magnesium intake is inade-
quate, the function of TRPM6 in active intestinal magne-
sium absorption and renal reabsorption become very
important. Further well-designed functional studies are
needed to investigate the molecular consequences of com-
mon genetic variability of TRPM6 and TRPM7 on mRNA
expression, splicing, and degradation and metabolic pro-
files.
The strengths of our study include a prospective study
design with up to 10 years of follow-up, careful collection
of DNA samples and baseline variables, and an effective
matching strategy used in a well-characterized study pop-
ulation. However, several limitations deserve further con-
sideration. First, our study had relatively small sample size
Cross-species comparison of the protein sequences of (A) two TRPM6 segments encompassing the two non-synonymous  SNPs, V1393I and K1584E (21 amino acids each, centered at the non-synonymous SNP) in human (GenBank accession number  Q9BX84), chimpanzee (GenBank accession number XP_528327), and mouse (GenBank accession number Q8CIR4); and (B) a  TRPM7 segment encompassing the non-synonymous SNP, T1482I (21 amino acids, centered at the non-synonymous SNP) in  human (GenBank accession number Q96QT4), Sheep (GenBank accession number ABP35923), mouse (GenBank accession  number Q923J1), and zebra fish (GenBank accession number NP_001025232) Figure 4
Cross-species comparison of the protein sequences of (A) two TRPM6 segments encompassing the two non-
synonymous SNPs, V1393I and K1584E (21 amino acids each, centered at the non-synonymous SNP) in human 
(GenBank accession number Q9BX84), chimpanzee (GenBank accession number XP_528327), and mouse (Gen-
Bank accession number Q8CIR4); and (B) a TRPM7 segment encompassing the non-synonymous SNP, T1482I 
(21 amino acids, centered at the non-synonymous SNP) in human (GenBank accession number Q96QT4), 
Sheep (GenBank accession number ABP35923), mouse (GenBank accession number Q923J1), and zebra fish 
(GenBank accession number NP_001025232). The asterisks denote amino acid residues conserved across all the species 
that were compared.BMC Medical Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2350/10/4
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and did not have the power to assess modest genetic
effects or interactions. The associations we identified
could have been caused by chance due to statistical fluctu-
ation; however, consistency with laboratory findings
makes our results plausible. Second, population stratifica-
tion may be a concern but unlikely to explain our find-
ings, because our populations are racially homogeneous,
with the majority of the participants being white
(>92.5%). Third, we lacked stable and reliable measures
of extracellular or intracellular magnesium status. Serum
magnesium may be a good indicator for severe magne-
sium deficiency but is not sensitive to suboptimal magne-
sium status. Finally, findings in this cohort of women of
predominantly European descent could not address pop-
ulation-specific genetic effects.
Conclusion
Our results suggest that two common non-synonymous
TRPM6 coding region variants might interact with magne-
sium intake in determining the risk of type 2 diabetes.
However, our findings could be caused by chance due to
multiple comparisons and insufficient statistical power;
additional studies are needed to confirm these results and
to further characterize the effects of genetic variation in
TRPM6 on magnesium homeostasis.
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